- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Organoids.
Displaying page 1 of 1.
| EudraCT Number: 2014-003965-11 | Sponsor Protocol Number: CC-TT-IMA-14 | Start Date*: 2015-11-18 |
| Sponsor Name:University Medical Center Utrecht | ||
| Full Title: Targeted therapy with Imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period. | ||
| Medical condition: colon cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-003811-13 | Sponsor Protocol Number: N14SNS | Start Date*: 2016-06-16 |
| Sponsor Name:Antoni van Leeuwenhoek - Netherlands Cancer Institute | ||
| Full Title: Selecting cancer patients for treatment using Tumor Organoids, the SENSOR study | ||
| Medical condition: Colorectal cancer and non-small cell lung cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-006276-16 | Sponsor Protocol Number: CTRIAL-IE-20-27 | Start Date*: 2022-03-09 | |||||||||||
| Sponsor Name:Cancer Trials Ireland | |||||||||||||
| Full Title: PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine. | |||||||||||||
| Medical condition: Metastatic refractory pancreatic cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001619-19 | Sponsor Protocol Number: TRIO-2016 | Start Date*: 2017-03-27 |
| Sponsor Name:UMC Utrecht | ||
| Full Title: Genistein as an add-on treatment for CF? | ||
| Medical condition: Cystic Fibrosis | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-000057-37 | Sponsor Protocol Number: ABBA-2014 | Start Date*: 2014-04-30 |
| Sponsor Name:University Medical Centre Utrecht | ||
| Full Title: A B2-agonist as a CFTR activator in CF | ||
| Medical condition: Cystic Fibrosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-003395-41 | Sponsor Protocol Number: EVIDENT | Start Date*: 2021-01-15 | |||||||||||
| Sponsor Name:Oslo University Hospital | |||||||||||||
| Full Title: An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived o... | |||||||||||||
| Medical condition: Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001181-38 | Sponsor Protocol Number: AuspiCiOus | Start Date*: 2021-07-29 |
| Sponsor Name:Academic Medical Center | ||
| Full Title: Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study | ||
| Medical condition: Gastroesophageal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-003697-52 | Sponsor Protocol Number: SYNCOPE-2021-V1 | Start Date*: 2020-09-16 | |||||||||||
| Sponsor Name:Helsinki University Hospital | |||||||||||||
| Full Title: Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases | |||||||||||||
| Medical condition: Rectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004497-21 | Sponsor Protocol Number: GASPAR | Start Date*: 2021-01-20 | |||||||||||
| Sponsor Name:Centre François Baclesse | |||||||||||||
| Full Title: Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A phase II study (GASPAR) | |||||||||||||
| Medical condition: Resectable gastric or gastroesophageal junction adenocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005792-12 | Sponsor Protocol Number: GOIRC-06-2020 | Start Date*: 2022-04-05 | |||||||||||
| Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
| Full Title: Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC) | |||||||||||||
| Medical condition: Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-004987-23 | Sponsor Protocol Number: RAS-Triplet | Start Date*: 2020-05-22 |
| Sponsor Name:UMC Utrecht | ||
| Full Title: A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan... | ||
| Medical condition: colorectal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-002123-15 | Sponsor Protocol Number: GEICAM/2019-01 | Start Date*: 2020-06-15 | |||||||||||
| Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama) | |||||||||||||
| Full Title: Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative hi... | |||||||||||||
| Medical condition: High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002940-17 | Sponsor Protocol Number: N16NCI | Start Date*: 2016-11-25 | |||||||||||
| Sponsor Name:Antoni van Leeuwenhoek | |||||||||||||
| Full Title: Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer | |||||||||||||
| Medical condition: stage 2-3 adenocarcinoma of the colon | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-002350-78 | Sponsor Protocol Number: ProBio | Start Date*: 2018-10-22 | ||||||||||||||||
| Sponsor Name:Karolinska Institutet | ||||||||||||||||||
| Full Title: ProBio: An outcome adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer | ||||||||||||||||||
| Medical condition: Patients with metastatic hormone-sensitive and castration-resistant prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
| Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.